# Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate

> **NCT06340789** · PHASE2 · UNKNOWN · sponsor: **National Cheng-Kung University Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Symptom, Cognitive
- Schizophrenia
- Schizo Affective Disorder

## Interventions

- **DRUG:** Sodium Benzoate 2gram/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06340789
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-10
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06340789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06340789, "Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodium Benzoate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06340789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*